280 related articles for article (PubMed ID: 30498682)
1. Interaction between platelets and endothelium: from pathophysiology to new therapeutic options.
Hamilos M; Petousis S; Parthenakis F
Cardiovasc Diagn Ther; 2018 Oct; 8(5):568-580. PubMed ID: 30498682
[TBL] [Abstract][Full Text] [Related]
2. Combined antiplatelet therapy: still a sweeping combination in cardiology.
Manolis AS; Manolis TA; Papadimitriou P; Koulouris S; Melita H
Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):136-67. PubMed ID: 23597106
[TBL] [Abstract][Full Text] [Related]
3. Current Status of Antiplatelet Therapy in Acute Coronary Syndrome.
Dash D
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):40-9. PubMed ID: 26245659
[TBL] [Abstract][Full Text] [Related]
4. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
Chyrchel B; Totoń-Żurańska J; Kruszelnicka O; Chyrchel M; Mielecki W; Kołton-Wróż M; Wołkow P; Surdacki A
Platelets; 2015; 26(6):593-7. PubMed ID: 25350775
[TBL] [Abstract][Full Text] [Related]
5. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction.
Gasecka A; Nieuwland R; Budnik M; Dignat-George F; Eyileten C; Harrison P; Huczek Z; Kapłon-Cieślicka A; Lacroix R; Opolski G; Pluta K; van der Pol E; Postuła M; Leroyer A; Siljander P; Sturk A; Filipiak KJ
Platelets; 2020; 31(1):26-32. PubMed ID: 30585111
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
[TBL] [Abstract][Full Text] [Related]
8. Course of platelet miRNAs after cessation of P2Y12 antagonists.
Jäger B; Stojkovic S; Haller PM; Piackova E; Kahl BS; Andric T; Vargas KG; Wojta J; Huber K
Eur J Clin Invest; 2019 Aug; 49(8):e13149. PubMed ID: 31172515
[TBL] [Abstract][Full Text] [Related]
9. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.
Schrottmaier WC; Kral JB; Badrnya S; Assinger A
Thromb Haemost; 2015 Aug; 114(3):478-89. PubMed ID: 25904241
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
11. High and low on-treatment platelet reactivity to P2Y
Ferreiro JL; Vivas D; De La Hera JM; Marcano AL; Lugo LM; Gómez-Polo JC; Silva I; Tello-Montoliu A; Marín F; Roldán I
Thromb Res; 2019 Mar; 175():95-101. PubMed ID: 30738371
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of clopidogrel.
Sarafoff N; Byrne RA; Sibbing D
Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
[TBL] [Abstract][Full Text] [Related]
13. Emerging P2Y12 receptor antagonists: role in coronary artery disease.
Oliphant CS; Doby JB; Blade CL; Das K; Mukherjee D; Das P
Curr Vasc Pharmacol; 2010 Jan; 8(1):93-101. PubMed ID: 19485932
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
[TBL] [Abstract][Full Text] [Related]
15. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
[TBL] [Abstract][Full Text] [Related]
16. Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y
Chyrchel B; Drożdż A; Długosz D; Stępień EŁ; Surdacki A
Int J Med Sci; 2019; 16(2):264-275. PubMed ID: 30745807
[No Abstract] [Full Text] [Related]
17. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Golino P
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
[TBL] [Abstract][Full Text] [Related]
18. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
[TBL] [Abstract][Full Text] [Related]
19. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
[TBL] [Abstract][Full Text] [Related]
20. New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Sinhal AR; Aylward PE
Clin Ther; 2013 Aug; 35(8):1064-8. PubMed ID: 23973039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
